Fecal Microbiota Transplantation:

What We Know, What We Don't, and What's Coming

Yoon Hang Kim, MD, MPH

September 2026

Introduction

Fecal microbiota transplantation (FMT) is one of the most vivid demonstrations that the gut microbiome is not a bystander in human disease. It transfers a processed, screened community of gut microorganisms—bacteria, bacteriophages, fungi, metabolites, microbial genes, and spores—from a healthy donor to a recipient whose ecosystem has lost the functions that normally resist pathogens, metabolize bile acids and fiber, and support barrier and immune homeostasis.

The field has matured considerably over the past several years. We now have FDA-approved microbiota products for a single indication, a growing body of controlled trial data across several diseases, a first-in-human signal in food allergy, and an increasingly sophisticated understanding of why FMT works when it does. This article reviews what is established, what remains investigational, and where the most important unanswered questions lie.

What FMT Actually Does

FMT is more than adding "good bacteria." It introduces an intact microbial ecosystem with the aim of restoring ecological function—not simply raising diversity scores. The important functional effects include:

Colonization resistance. Donor-derived organisms compete with pathogens for nutrients and niches, produce inhibitory metabolites, and help prevent pathogen expansion. This is the core mechanism behind its success in recurrent Clostridioides difficile infection (rCDI).

Bile-acid restoration. A disrupted microbiome often loses organisms that convert primary bile acids to secondary forms. Secondary bile acids suppress C. difficile germination and outgrowth, whereas an excess of primary bile acids can favor it. This same pathway has emerged as a potential mechanism in food-allergy research (Weingarden et al., 2014; Seekatz et al., 2018).

Short-chain fatty acid (SCFA) production. Restoration of fiber-fermenting organisms increases acetate, propionate, and especially butyrate. Butyrate fuels colonocytes, supports epithelial tight junctions, and is associated with regulatory rather than pro-inflammatory immune signaling (Sorbara & Pamer, 2022).

Barrier and immune effects. Microbial metabolites and structural signals influence mucus production, epithelial repair, IgA responses, innate immunity, and the Treg/Th17 balance. These mechanisms are biologically plausible and active areas of research, but they do not by themselves prove a clinical benefit for every disease.

A useful clinical framing: FMT is a microbial ecosystem restoration therapy—not a general-purpose probiotic, a detoxification treatment, or a longevity intervention.

Where the Evidence Is Established

Recurrent C. difficile Infection: The Benchmark

Recurrent C. difficile infection remains the one setting where FMT has moved from investigational to standard clinical use. The 2024 American Gastroenterological Association guideline supports fecal microbiota-based therapies after standard antibiotics in immunocompetent adults with rCDI and permits selective conventional FMT in mildly or moderately immunocompromised adults. The guideline recommends against these therapies in severely immunocompromised adults (Peery et al., 2024).

Two FDA-approved, donor-derived microbiota products are now available in the United States for preventing recurrent CDI after antibiotic treatment:

Neither product treats an active acute CDI episode by itself; the approved use is prevention of recurrence after antimicrobial treatment. This distinction matters because it reflects what we actually understand—FMT reconstitutes colonization resistance and bile-acid metabolism that antibiotics and recurrent CDI have disrupted. It does not eradicate an active infection.

Severe or Fulminant CDI

For severe or fulminant CDI unresponsive to standard treatment, selective use at experienced centers is guideline-supported. The rationale is that FMT may interrupt the cycle of ongoing dysbiosis and pathogen amplification, and in selected cases may avert colectomy. This remains a specialized, case-by-case decision rather than a routine intervention.

Active Research: Where the Field Is Headed

Food Allergy — A Breakthrough Signal

The most striking recent development is a first-in-human proof-of-concept trial for peanut allergy. The open-label phase 1 study (NCT02960074), published in Science Translational Medicine in August 2026, enrolled 15 adults with severe peanut allergy who reacted at ≤100 mg peanut protein during baseline double-blind, placebo-controlled food challenges (Rachid et al., 2026).

Participants received oral, frozen encapsulated donor-stool preparations. The results:

Response was defined by improvement from a baseline threshold of ≤100 mg peanut protein to 300 or 600 mg on repeat blinded food challenges, with the increase still present at the four-month clinical endpoint. No serious FMT-related adverse events or FMT-triggered allergic reactions were reported (Rachid et al., 2026).

Why This Matters—And Why Caution Remains Necessary

In some participants, FMT shifted the reaction threshold from roughly a trace exposure toward the range of one to several peanuts. That could reduce the risk from accidental exposure—the most realistic near-term therapeutic goal. But the study was open label, small, and lacked a placebo comparator. Contributions from natural threshold variability, challenge effects, behavioral factors, and regression to the mean cannot be excluded.

The mechanistic findings are what make this study particularly compelling. In human responders, investigators found increased RORγt-positive regulatory T cells—a gut-associated tolerogenic phenotype relevant to oral tolerance—and decreased Th2 cell activity, consistent with a shift away from the allergic IL-4/IL-5/IL-13 program. Post-FMT microbiomes from human responders protected mice from food allergy, and that protection was associated with increased colonization by Bacteroides and increased bile-acid metabolites (Rachid et al., 2026).

The causal experiment is especially notable: a candidate protective Bacteroides strain lost its ability to suppress food allergy in mice when its bile salt hydrolase gene was deleted. This does not prove one strain or one enzyme will treat human peanut allergy, but it strengthens the hypothesis that microbial bile-acid transformation is one causal pathway in oral tolerance—not merely a bystander biomarker.

The Phase 2 Trial

A phase 2 study (NCT05695261) is underway, directly addressing the major limitations of the phase 1 work. It is randomized, double-blind, and placebo-controlled, and it includes an OIT combination arm testing whether microbiota therapy can improve sustained unresponsiveness after peanut oral immunotherapy is stopped.

Ulcerative Colitis

FMT can induce remission in a subset of ulcerative-colitis patients in clinical trials, especially with intensive multidose protocols, anaerobic handling, selected donor pools, and sometimes multi-donor products. Responders in trials often show increased donor-type obligate anaerobes, SCFA-producing taxa such as Roseburia and Eubacterium, and recovery of secondary bile-acid pathways. However, effect sizes vary considerably by donor pool, anaerobic processing, dose frequency, route, concomitant therapy, and disease phenotype. The AGA recommends conventional FMT for ulcerative colitis only in the context of clinical trials (Peery et al., 2024).

Hepatic Encephalopathy

This is a serious emerging indication. In a small randomized clinical trial in men with cirrhosis and recurrent hepatic encephalopathy, a rationally selected donor FMT protocol following antibiotic pretreatment was associated with fewer serious adverse events, fewer recurrent HE episodes, improved cognition, and improved dysbiosis compared with standard care alone (Bajaj et al., 2017). The THEMATIC trial, a subsequent placebo-controlled dose and route study, has further advanced the field, though FMT for hepatic encephalopathy remains investigational (Bajaj et al., 2025).

Atopic Dermatitis

Atopic dermatitis is the non-food-allergy application with some of the most substantial early human data. A proof-of-concept study in adults with moderate-to-severe AD reported symptom improvement after repeated FMT sessions (Mashiah et al., 2022). A later randomized, double-blind exploratory trial in moderate-to-severe AD showed further signal (Liu et al., 2025), but these remain early, single-study signals rather than a basis for routine clinical FMT.

Other Conditions Under Investigation

Important Scientific Discoveries Reshaping the Field

Function Over Taxonomy

Earlier FMT work emphasized alpha-diversity and lists of "good" versus "bad" taxa. Current work increasingly focuses on whether a transferred community restores actual ecological functions: secondary bile-acid generation, butyrate synthesis, carbohydrate utilization, oxygen depletion in the colon, and resistance to pathogen invasion. A recipient may improve clinically without looking like a taxonomic copy of the donor.

Engraftment Is Selective, Not Wholesale

Donor strains do not uniformly or permanently replace a recipient's microbiome. Engraftment depends on baseline ecological niches, antibiotic exposure, donor composition, route, diet, host immunity, and disease context. Lower baseline diversity may leave more available niches and can be associated with greater donor-strain engraftment. This helps explain the "super-donor" phenomenon—some donors, preparations, and microbial functions appear substantially more effective than others—and makes one-size-fits-all FMT biologically implausible.

Metabolomics Is Becoming Central

Clinical response in rCDI and, less consistently, ulcerative colitis has been linked to recovery of secondary bile acids (relevant to pathogen suppression and epithelial/immune signaling), SCFAs—particularly butyrate—and tryptophan-derived metabolites that signal through aryl hydrocarbon receptor systems and may affect mucosal immunity (Sorbara & Pamer, 2022). The field is shifting from "Which species should be present?" to "Which ecological pathways must be restored?"

The Virome and Nonbacterial Components

Classic FMT was treated as a bacterial intervention. Newer work considers bacteriophages, fungi, archaea, and the metabolite cargo of the transplant. Fecal virome transplantation—using filtered viral fractions—is an early experimental approach intended to modify bacterial communities without delivering whole stool. Interesting, but far from established practice.

Defined Consortia May Replace Donor Stool

The field is moving toward more standardized, safer products: purified spore preparations, consortia of defined cultured commensal strains, rationally selected strains matched to a missing function (such as bile-acid conversion), and potentially autologous stool banking before high-risk antibiotic exposure, chemotherapy, or transplantation. The attraction is lot consistency, traceability, and tighter pathogen control. The trade-off is that a defined consortium may omit unknown beneficial components of an intact ecosystem.

Safety and Implementation Cautions

FMT involves transfer of living biological material and viable organisms. Safety is not a theoretical concern.

Transmitted infection is real. Historical safety alerts have involved multidrug-resistant organisms and enteric pathogens. The FDA has required intensified donor risk assessment and testing, including nucleic-acid testing for enteropathogenic E. coli and Shiga toxin-producing E. coli, with donation-lot quarantine procedures. Additional safety protections address potential SARS-CoV-2 transmission through donor screening, testing, exclusion criteria, and explicit informed consent (FDA, 2020a; FDA, 2020b).

Risk is context-dependent. Frail, critically ill, severely immunocompromised, neutropenic, or recent hematopoietic-cell-transplant patients need especially cautious specialist evaluation. The AGA recommends against fecal microbiota-based therapies for rCDI prevention in severely immunocompromised adults (Peery et al., 2024).

Common short-term effects include transient bloating, cramping, diarrhea or constipation changes, nausea, and procedural risks if delivered by colonoscopy or upper-GI routes.

Long-term trait transfer remains uncertain. Concerns include transmission of antimicrobial-resistance genes and potentially undesirable metabolic or immune traits. Long-term registry experience has been generally reassuring, but absence of a strong signal is not proof of absence of risk.

DIY FMT is unsafe. A "healthy-looking" donor is not an adequately screened donor, and home processing lacks validated testing, containment, and traceability. Direct-to-consumer or unscreened stool transfer should not be performed.

Bottom Line

FMT has proven that microbiome manipulation can produce a major clinical effect—but mainly in the narrowly defined setting of recurrent C. difficile infection, where it corrects a very specific ecological failure induced by antibiotics. Beyond CDI, the most compelling new signal is in food allergy, where a coherent immune-metabolic mechanism involving RORγt-positive Tregs, Bacteroides engraftment, and bile-acid transformation has been linked to a modest but real increase in peanut reaction threshold in humans (Rachid et al., 2026).

The major late realization is that success depends not on transferring diverse bacteria, but on restoring durable ecosystem functions—colonization resistance, bile-acid conversion, SCFA production, mucosal barrier support, and appropriate immune signaling. That insight is driving the field toward standardized live biotherapeutics and defined microbial consortia rather than broad, empiric use of donor stool.

For a patient without recurrent CDI, FMT should be treated as a trial-only intervention unless there is a specific, evidence-supported indication managed through a GI or infectious-disease program with formal donor screening and adverse-event surveillance.

References

1. Rachid R, Martinez-Blanco M, Kuziel GA, et al. Fecal microbiome transplant in food allergy in humans and mice identifies a role for bile acid metabolites in oral tolerance. Sci Transl Med. 2026;18(861):eaee3263. doi:10.1126/scitranslmed.aee3263

2. ClinicalTrials.gov. NCT02960074: Evaluating the Safety and Efficacy of Oral Encapsulated Fecal Microbiota Transplant in Peanut Allergic Patients. https://clinicaltrials.gov/study/NCT02960074

3. ClinicalTrials.gov. NCT05695261: Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients. https://clinicaltrials.gov/study/NCT05695261

4. National Institutes of Health, Research Matters. Microbiome transplants may curb food allergies. September 8, 2026. https://www.nih.gov/news-events/nih-research-matters/microbiome-transplants-may-curb-food-allergies

5. Peery AF, Kelly CR, Kao D, et al. AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases. Gastroenterology. 2024;166(3):409–434. doi:10.1053/j.gastro.2024.01.008

6. U.S. Food and Drug Administration. VOWST (fecal microbiota spores, live-brpk). https://www.fda.gov/vaccines-blood-biologics/vowst

7. U.S. Food and Drug Administration. REBYOTA (fecal microbiota, live-jslm). https://www.fda.gov/vaccines-blood-biologics/vaccines/rebyota

8. U.S. Food and Drug Administration. Information Pertaining to Additional Safety Protections Regarding Use of Fecal Microbiota for Transplantation—Testing of Stool Donors for Enteropathogenic Escherichia coli and Shigatoxin-Producing Escherichia coli. April 6, 2020. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/information-pertaining-additional-safety-protections-regarding-use-fecal-microbiota-transplantation

9. U.S. Food and Drug Administration. Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Additional Safety Protections Pertaining to SARS-CoV-2 and COVID-19. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/safety-alert-regarding-use-fecal-microbiota-transplantation-and-additional-safety-protections

10. Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology. 2017;66(6):1727–1738. doi:10.1002/hep.29306

11. Bajaj JS, Fagan A, Gavis EA, et al. Microbiota transplant for hepatic encephalopathy in cirrhosis: the THEMATIC trial. J Hepatol. 2025;83(1):81–91. doi:10.1016/j.jhep.2024.12.047

12. Mashiah J, Karady T, Fliss-Isakov N, et al. Clinical efficacy of fecal microbial transplantation treatment in adults with moderate-to-severe atopic dermatitis. Immun Inflamm Dis. 2022;10(3):e570. doi:10.1002/iid3.570

13. Liu X, Luo Y, Chen X, et al. Fecal microbiota transplantation against moderate-to-severe atopic dermatitis: a randomized, double-blind controlled explorer trial. Allergy. 2025;80(5):1377–1388. doi:10.1111/all.16372

14. Sorbara MT, Pamer EG. Microbiome-based therapeutics. Nat Rev Microbiol. 2022;20:365–380. doi:10.1038/s41579-021-00667-9

15. Seekatz AM, Theriot CM, Rao K, et al. Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection. Anaerobe. 2018;53:64–73. doi:10.1016/j.anaerobe.2018.04.001

16. Weingarden AR, Chen C, Bobr A, et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol. 2014;306(4):G310–G319. doi:10.1152/ajpgi.00282.2013

17. Sciencedirect. Long-term safety of fecal microbiota transplantation: registry experience. Gastroenterology. 2024. doi:10.1016/S0016-5085(24)00416-X

18. Nature. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Exp Mol Med. 2021;53:1166–1175. doi:10.1038/s12276-021-00627-6

This article is intended for educational purposes and does not constitute medical advice. FMT for any condition other than recurrent C. difficile infection should be pursued only through properly supervised clinical trials or evidence-supported programs with formal donor screening and adverse-event monitoring.